# Professional Summary This clinical guidance document addresses post-operative discharge advice for patients following cerebral aneurysm clipping, a surgical procedure in which an aneurysm is secured using a metal clip to prevent rupture. The article provides comprehensive recommendations for managing patients in the immediate post-operative period and during their recovery at home. Key aspects covered include activity restrictions, medication management, symptom monitoring, and follow-up care protocols that patients should observe after undergoing aneurysm clipping surgery. The guidance emphasizes the importance of patient education regarding warning signs of complications, such as increased headache, vision changes, or neurological deterioration, which may indicate post-operative issues requiring immediate medical attention. This resource is significant for neurosurgical teams, discharge planners, and primary care providers involved in supporting aneurysm patients' recovery trajectories, ensuring consistent, evidence-based post-operative management that optimizes patient outcomes and reduces readmission rates following this critical neurosurgical intervention.

Lacunar stroke management follows standard acute ischemic stroke protocols, prioritizing medical stability and thrombolysis eligibility assessment. Intravenous thrombolysis using tissue plasminogen activator (tPA) remains the mainstay treatment when administered within 4.5 hours of symptom onset. Tenecteplase has emerged as the preferred thrombolytic agent based on phase 3 trials demonstrating noninferiority to alteplase with simpler single-bolus administration, as endorsed by the 2026 AHA/ASA guidelines. Alteplase remains an alternative option. For patients with salvageable ischemic penumbra detected on CT/MRI perfusion imaging who present within nine hours of symptom onset, intravenous thrombolysis is recommended. Antiplatelet therapy should be delayed 24 hours post-thrombolysis pending neuroimaging confirmation of no intracranial hemorrhage. The ongoing LAC-3 trial is evaluating cilostazol and isosorbide mononitrate efficacy for preventing adverse outcomes in small vessel lacunar stroke. Mechanical thrombectomy indications have expanded beyond the traditional six-hour window to 16-24 hours, supported by the DAWN and DEFUSE 3 trials, utilizing advanced CT or MRI perfusion imaging for candidate selection.

Cerebral aneurysms, bulges in cerebral arteries, pose severe risks if ruptured, with approximately half of patients experiencing death or severe disability. While endovascular treatment has long offered a minimally invasive approach, traditional coil embolization presents significant challenges, particularly with wide-neck aneurysms where coils risk migrating into the parent artery. The introduction of the Woven EndoBridge (WEB) device has fundamentally transformed acute aneurysm management. Unlike coiling, which requires stent placement and prolonged dual antiplatelet therapy (DAPT), the WEB mesh basket is deployed directly within the aneurysm to disrupt blood flow and induce thrombosis without exposing the parent artery to metal. This eliminates the need for extended DAPT, a critical advantage in ruptured cases where additional interventions like external ventricular drainage or craniotomy may be needed. The simplified procedural steps—requiring only single WEB placement versus the complex coiling sequence—have reduced operative times to less than half compared to traditional methods. The WEB represents a paradigm shift in acute cerebral aneurysm treatment, offering clinically superior outcomes with reduced procedural complexity and medication burden.

Mechanical thrombectomy represents the standard treatment for acute ischemic stroke caused by large vessel occlusions. This systematic review compared the radially adjustable Tigertriever device with conventional self-expanding stent retrievers (SE-SRs), which deploy with fixed radial force. Researchers conducted a comprehensive search across PubMed, Cochrane, Embase, and ClinicalTrials.gov following PRISMA guidelines, analyzing three retrospective cohort studies encompassing 476 patients: 210 treated with Tigertriever and 266 with SE-SRs. The analysis evaluated successful reperfusion rates using the modified Thrombolysis in Cerebral Infarction scale, procedural adverse events including vasospasm and perforation, symptomatic intracranial hemorrhage within 24 hours, functional independence at 90 days, and mortality. Tigertriever demonstrated significantly superior efficacy, achieving successful reperfusion in 82.8% of cases compared to 77.8% with SE-SRs (odds ratio 1.74, p=0.03). The operator-controlled, radially adjustable design of Tigertriever allows tailored expansion and modulation of vessel wall pressure, providing clinicians with enhanced flexibility during thrombectomy procedures. These findings suggest Tigertriever may offer improved outcomes for patients with large vessel occlusions across multiple intracranial locations including the internal carotid artery, middle cerebral artery, and basilar artery.

# Professional Summary This systematic review examines the clinical outcomes and hemodynamic effects of flow diversion treatment for proximal superior cerebellar artery aneurysms, published in Neurosurgical Review in July 2026. Flow diversion represents an endovascular technique that uses specialized stents to redirect blood flow away from aneurysms, promoting thrombosis while preserving parent vessel patency. The research synthesizes existing clinical data to evaluate the safety and efficacy of this approach for this challenging anatomical location, which historically posed significant treatment difficulties due to the vessel's complex branching patterns and eloquent surrounding anatomy. The study includes an exploratory hemodynamic analysis to understand the mechanisms underlying flow diversion success in these cases. By characterizing clinical outcomes including aneurysm occlusion rates, retreatment requirements, and complication profiles, this work provides critical evidence for optimal management strategies. These findings are significant for neurosurgeons and neurointerventionalists treating complex proximal superior cerebellar artery aneurysms, offering evidence-based guidance for patient selection and treatment planning while advancing understanding of flow diversion biomechanics in challenging anatomical scenarios.

In this multicenter retrospective cohort of distal small-vessel flow diversion with the p48 MW HPC, prasugrel-based SAPT was not associated with a significant increase in thromboembolic/ischemic events compared with DAPT; angiographic occlusion and hemorrhage signals were exploratory, with numerically fewer intracranial hemorrhages under SAPT without statistical significance.

Flow diverting stent (FDS) devices have revolutionized the treatment of large and complex brain aneurysms, but there is still room for improvement, particularly on the flow diversion properties and technical challenges associated with stent deployment. In this study we compared flow diversion properties between the new generation Surpass Evolve (Stryker) and the Pipeline Flex (Medtronic) devices by quantitatively evaluating intra-aneurysmal flow modification.

The flow diversion effects of both stents were limited to flow velocity reduction. In a non-thrombosed aneurysm or an aneurysm with delayed thrombosis, the intra-aneurysmal pressure remains essentially unchanged regardless of the level of the intra-aneurysmal flow velocity reduction induced by the stents.

When widely applied, standardization of methods of measuring and reporting outcomes will help to harmonize the assessment of treatment outcomes in clinical studies, help facilitate communication of results among specialists, and help enable research and development to focus on specific aspects of FD techniques and technology.

Non-traumatic subarachnoid hemorrhage, primarily caused by intracranial aneurysms accounting for 70–80 percent of cases, requires urgent treatment to prevent mortality and rebleeding. This single-center study from One Brooklyn Health-Downstate Health Science University examines neuro-endovascular repair of ruptured basilar artery bifurcation aneurysms, including cases with poor clinical grades. Historically, microsurgical clipping served as the gold standard treatment with approximately 90 percent complete occlusion rates, though data predominantly focused on anterior circulation aneurysms. The emergence of endovascular coiling in the early 1990s offered a less invasive alternative with reduced morbidity and shorter hospital stays. The landmark 2005 International Subarachnoid Aneurysm Trial demonstrated endovascular coiling's advantages over surgical clipping. This research, led by Dr. Yahia M. Lodi, Chief of Neurointerventional Surgery, addresses the gap in posterior circulation treatment data by evaluating endovascular techniques for basilar artery bifurcation aneurysms in high-risk patients, potentially establishing optimal treatment protocols for this critical vascular pathology.

Researchers have developed an advanced computational framework to accurately model the deployment mechanics of the Contour Neurovascular System (CNS), an intrasaccular flow disruptor device used to treat wide-neck intracranial aneurysms. Previous patient-specific models oversimplified deployment by prescribing pre-seated geometries, neglecting critical biomechanical factors like neck coverage, wall apposition, and migration resistance. The new contact-resolved finite-element approach explicitly simulates device deployment within patient-specific vascular environments, representing the CNS's dual-layer interwoven Nitinol braid using geometrically exact beams and the vascular wall as a deformable hyperelastic shell. Analysis across three anatomical phenotypes revealed that final device morphology is highly sensitive to friction and release depth, with frictionless assumptions permitting excessive sliding while near-stick conditions enhance anchoring but restrict compliance. Conventional geometric placement methods fail to capture these critical contact interactions and wall-supported mechanical equilibrium. This biomechanically grounded framework provides a foundation for downstream hemodynamic and fluid-structure interaction modeling, advancing endovascular treatment planning for intracranial aneurysms—conditions with high morbidity and mortality if ruptured.

Hemocompatible coatings represent a critical strategic decision in medical device development, with choices between heparin and non-heparin formulations, varying dwell times, and animal-derived versus synthetic materials each carrying distinct clinical, regulatory, and manufacturing implications. Surmodics emphasizes that successful hemocompatibility integration requires early engagement during the feasibility stage, treating coating selection as a core development decision rather than a final specification. This approach ensures that coating choices align with the device's clinical profile and regulatory pathway, ultimately shaping validation strategies, regulatory defensibility, and long-term durability. The optimal coating system emerges through structured evaluation of clinical use requirements, dwell time specifications, substrate compatibility, and regulatory considerations, rather than defaulting to the first proposed solution. By prioritizing hemocompatibility decisions early in development, companies can establish foundations that support successful regulatory submission and sustained clinical performance throughout the device lifecycle.

When metallic stents or flow-diverters are placed in cerebral vessels, the exposed metal struts trigger thrombosis until they become covered by endothelium—a process that takes weeks to months. Unlike simple coiling, these devices create a thrombogenic foreign surface in direct contact with flowing blood. Without antiplatelet therapy, the risk of acute stent thrombosis is unacceptably high, resulting in devastating stroke or death in the majority of cases.

Anterior communicating artery (AComA) aneurysms remain challenging because of their complex anatomy, rupture risk, and proximity to vital structures. This study compared the long-term durability, retreatment rates, complications, and outcomes of microsurgical clipping and endovascular treatment. This retrospective study included 313 patients (≥ 18 years) with ruptured or unruptured AComA aneurysms treated at a single center (2006–2024). Patients were categorized by treatment modality into two groups: (1) Microsurgical clipping and (2) Endovascular treatment.

Although the quality of evidence is lower than for coronary interventions due to a lower number of patients and procedures, neurointerventional antiplatelet and antithrombotic management shares several themes. Prospective and randomized studies are needed to strengthen the data supporting these recommendations.

Thromboembolic events rarely occurred beyond 30 days after SAC/FD. The duration of DAPT may be shortened if patients have a periprocedural period without events. Further prospective studies are warranted to determine the optimal duration of antiplatelet therapy.

Angioscopy reliably confirmed neointimal coverage 6 months after FD placement, suggesting the potential for safe DAPT discontinuation. The findings underscore the superiority of angioscopy over cone-beam CT in identifying thin neointima. Further studies involving larger cohorts and applying advanced imaging technologies are required to optimize post-FD antiplatelet therapy.

Mechanical thrombectomy represents a significant advancement in acute ischemic stroke treatment, extending therapeutic intervention possibilities beyond the traditional six-hour window. This research examines functional outcomes in patients who undergo mechanical thrombectomy after this extended timeframe, challenging conventional treatment paradigms. The study evaluates recovery trajectories and clinical efficacy in late-presentation cases, providing critical evidence for treatment decision-making in extended time windows. These findings have substantial implications for stroke management protocols and patient prognosis assessment, potentially broadening treatment eligibility criteria and improving long-term functional recovery prospects for stroke patients who arrive at medical facilities beyond the standard intervention period.

Hemocompatible coatings represent a critical strategic decision in medical device development, not merely a finishing specification. Manufacturers must evaluate multiple pathways—heparin versus non-heparin formulations, varying dwell times, and animal-derived versus synthetic materials—each with distinct clinical, regulatory, and manufacturing implications. Engaging coating selection during feasibility stages ensures decisions align with the device's clinical profile and regulatory strategy, ultimately determining validation viability and long-term durability. The optimal coating emerges from systematic evaluation of clinical use requirements, substrate compatibility, dwell time, and regulatory considerations rather than initial recommendations.

Researchers at Friedrich-Alexander-University Erlangen-Nürnberg have developed a compact, top-loading robotic system designed to enhance robot-assisted endovascular interventions. The innovative platform addresses significant limitations in existing systems by enabling continuous translational and rotational manipulation of standard endovascular instruments while facilitating rapid instrument exchange without reconfiguring the setup. Utilizing pneumatically actuated membrane grippers and a leader-follower control strategy, the system demonstrated impressive performance in motion-tracking experiments, achieving mean relative tracking errors of 3.6% for translational motion and 4.1% for rotational motion. Subsequent in vitro vascular phantom studies confirmed the system's feasibility for navigating to target locations. This advancement promises substantial clinical benefits, including reduced radiation exposure, improved surgeon ergonomics, and enhanced procedural precision while maintaining workflow integration.